Crystallization development and scale-up is always a challenge since the product properties must meet up to the intended functionality, stability, and safety of the final product. Our teams have more than 30 years of experience in the field and are leading experts in the area globally.
Our experts are experienced in supporting crystallization processes and supporting product development, by providing deeper insight into the solid-state properties of drug substance.
Magle AB (formed in 1995 as a pure development company) acquired Chemoswed AB (formed in 1944 as a manufacturing company) in 2016 before merging the companies in 2017 to form Magle Chemoswed. In 2019, Adroit Science AB was acquired to increase the development services segment. In 2021, PharmaCept GmbH was acquired as a first step to develop a sales and marketing organization for DSM products. Most recent to join the Magle Group is Magle Biopolymers - a CDMO part of the group focusing on Dextran technology.
Let’s recruit together and find your next colleague.